PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events

@article{Agell2011PI3KSP,
  title={PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events},
  author={Laia Agell and S. Hern{\'a}ndez and M. Salido and S. D. Muga and N. Juanpere and M. Arum{\'i}-Ur{\'i}a and S. Men{\'e}ndez and M. Lorenzo and J. Lorente and S. Serrano and J. Lloreta},
  journal={Modern Pathology},
  year={2011},
  volume={24},
  pages={443-452}
}
The phosphatidylinositol 3-kinase (PI3K)–AKT and RAS–MAPK pathways are deregulated in a wide range of human cancers by gain or loss of function in several of their components. Our purpose has been to identify genetic alterations in members of these pathways in prostate cancer. A total of 102 prostate tumors, 79 from prostate cancer alone (group G1) and 23 from bladder and prostate cancer patients (G2), are the subject of this study. In 20 of these 23, the bladder tumors were also analyzed… Expand
From genomics to functions: preclinical mouse models for understanding oncogenic pathways in prostate cancer.
Identification of frequent BRAF copy number gain and alterations of RAF genes in chinese prostate cancer
KRAS, BRAF, PIK3CA mutation frequency of radical prostatectomy samples and review of the literature
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 40 REFERENCES
Genetic alterations in the PI3K pathway in prostate cancer.
Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population.
Oncogenic PI3K and its role in cancer
PIK3CA mutations in nasopharyngeal carcinoma
BRAF and KRAS mutations in prostatic adenocarcinoma
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.
...
1
2
3
4
...